Iotrolan demonstrated significantly better patient tolerance than iohexol in a Phase III clinical trial for myelography contrast media. Opacification was comparable between the two nonionic dimeric contrast agents.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: